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Abstract 
Significance. Mesenchymal stem cells (MSCs), adult stem cells with the 
potential of differentiation into mesodermal lineages, play an important role in tissue 
homeostasis and regeneration. In different organs, a subpopulation of MSCs is 
located near to the vasculature and possibly represents the original source of 
lineage-committed mesenchymal progenitors. Recent Advances. The plasticity and 
immune characteristics of MSCs render them a preferential tool for regenerative cell 
therapy. Critical Issues. The culture expansion needed before MSC transplantation 
is associated with cellular senescence. Moreover, accelerated senescence of the 
total and perivascular MSC pool has been observed in humans and mouse models 
of premature aging disorders. MSC dysfunction is acknowledged as a culprit for the 
aging-associated degeneration of mesodermal tissues, but the underlying epigenetic 
pathways remain elusive. This article reviews current understanding of mechanisms 
impinging upon MSC health, including oxidative stress, Nrf2-ARE activity, sirtuins, 
non-coding RNAs, and PKCs. Future Directions. We provide evidence that 
epigenetic profiling of MSCs is utilitarian to the prediction of therapeutic outcomes. In 
addition, strategies that target oxidative stress-associated mechanisms represent 
promising approaches to counteract the detrimental effect of age and senescence in 
MSCs. 
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Introduction 
Understanding the aging process and the mechanisms underpinning the 
development of aging-associated diseases represents one of the most important 
endeavors of modern medical research. The death rate at all ages has been 
dramatically reduced in recent decades, resulting in a remarkable increase in life 
expectancy. However, increased lifespan also correlates with an increasingly old 
population and an increased number of individuals with chronic pathologies often 
requiring hospitalization. 
Accumulating evidence suggests that stem cells play a crucial role in 
controlling physiological homeostasis and rate of aging and stem cell exhaustion is 
considered as one of the hallmarks of aging (67,69). Hence, maintenance of a stem 
cell health may translate in postponing aging-related diseases. The loss of stem cell 
activity and acquisition of a senescent phenotype is due to both intrinsic factors, 
such as DNA damage, telomeres shortening and chromatin modifications (as 
reviewed in (9)) and external factors involving the stem cell microenvironment 
(cytokines stimulation (74)) and widespread damage in tissues. Senescence has a 
dualistic function: from one side protects cells from damages and oncogene 
activation but from the other limits the possibility for tissue regeneration triggering 
aging-related deterioration. In the last decades, mesenchymal stem cells (MSCs) 
have been investigated as therapeutic tools for regenerative medicine especially for 
treating chronic diseases. However, the possible impact of pathologic conditions on 
MSC viability and function has to be taken into account. In addition, MSCs numerical 
reduction or dysfunction can be per se cause of pathologies (101). For instance, 
accelerated attrition of the MSCs pool has been observed in premature aging 
disorders, including Werner syndrome (WS) and Hutchinson-Gilford progeria 
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syndrome (66,124). It is thus clear that these cells, although harbouring multilineage 
regeneration potential, may manifest intrinsic defects compromising their use in 
regenerative medicine. Conversely, transplantation of young MSCs increases the 
lifespan and fitness of progeroid phenotype as observed in mice (62). However, the 
genetic and epigenetic mechanisms underpinning MSC-mediated senescence have 
not been fully elucidated. 
This article reviews current understanding of the contribution of oxidative 
stress as a trigger of modifications at DNA and RNA leading to MSC aging and 
senescence (Figure 1). We also discuss how a quality and quantity assessment of 
these aging-related modifications can help upgrade current regenerative medicine 
approaches. 
 
The nature of MSCs and their potential for therapy 
In human, MSCs can be isolated from different adult tissues, including bone 
marrow where they were first discovered in 1970, skeletal muscle, adipose tissue, 
umbilical cord, synovium, the circulatory system, dental pulp, amniotic fluid, fetal 
blood, liver, and lung (as reviewed in (85)). Minimal characterization criteria helped 
to standardize MSC isolation and allowed the definition of MSCs as plastic adherent 
lineage-negative cells, expressing CD105, CD73, CD90 and potentially able to 
differentiate at least to osteocytes, chondrocytes, and adipocytes (42). Recently, new 
criteria including markers of potency have been recommended (33). Despite their 
low abundance (in the bone marrow their yield spans between 0.01 to 0.001% of 
nucleated cells (86)), MSCs are thought to be one of the most useful cell sources for 
clinical application in tissue regeneration. Indeed, compared to embryonic stem cells, 
MSCs are safe and non-immunogenic. 
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Although normally in a quiescent state, MSCs can re-enter the cell cycle and 
differentiate following specific stimuli like tissue injury. Thus, MSCs are important in 
guiding the processes of healing and tissue regeneration (83). In addition, MSCs are 
not only able to give rise to the cell types found in the tissue they were isolated from, 
but they can differentiate in a variety of mesodermal cell types and also differentiate 
into cell types of other germinal layers through a process known as 
transdifferentiation (85). 
Great relevance has been attributed to perivascular mesenchymal cells, which 
possibly represents the original source of lineage-committed mesenchymal 
progenitors. These cells are better known as pericytes. In vitro, pericytes show 
typical mesenchymal properties with the capacity to attach to tissue culture plastic, 
expand for multiple passages and differentiate into osteogenic, chondrogenic, or 
adipogenic lineages (23). In vivo lineage tracing studies have reported pericytes as 
progenitors of white adipocytes (102), follicular dendritic cells (59) and skeletal 
muscle (25,26). Pericytes have also been proposed to give rise to neurons, 
astrocytes, and oligodendrocytes (27) and to play a major role as fibroblast 
progenitors in fibrotic responses (34,38). However, in a very recent paper from 
Guimarães-Camboa, the mesenchymal origin and properties of pericytes were called 
into question using fate mapping experiments in murine models. Using the 
transcription factor Tbx18 as an embryonic pericyte marker, Guimarães-Camboa and 
co-workers demonstrated Tbx18-positive cells also co-express pericyte markers 
CD146 and neural/glial antigen 2 (NG2), but they do not differentiate during the 
development in any mesenchymal lineage (40). These results challenge the current 
view of endogenous pericytes as multipotent tissue-resident progenitors and suggest 
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that the plasticity observed in vitro or following transplantation in vivo arises from 
artificial cell manipulations ex vivo.  
 
MSCs in regenerative medicine: state-of-the-art 
MSCs represent a great promise for regenerative medicine. They can help the 
repair of injured organs and their functional recovery by migrating and homing at the 
injury site (71,109). This can be achieved by both transplanting purified MSCs from a 
donor (especially in a syngeneic fashion) or stimulating their activation in vivo from 
the reservoir located in situ. Moreover, MSCs can repair injured tissues by directly 
differentiating to functional cell of the tissue, favouring angiogenesis or paracrinally, 
stimulating resident progenitors activation (90). Paracrine factors released from 
transplanted or resident MSCs can also contribute to immunosuppression of the host 
in order to avoid an immune response. This effect seems to be exerted by both 
paracrine suppression of lymphocyte T and favouring the transition of macrophage 
from subtype M1 (pro-inflammatory) to M2 (anti-inflammatory). Moreover, MSCs 
secretome is also involved in paracrine protection against apoptosis and oxidative 
stress (reviewed in (64)). In the recent years, the role of microparticles as a 
component of MSCs secretome has been envisioned as a new tool in regenerative 
medicine. Those particles promote the horizontal transfer of mRNAs, microRNAs 
(miRs), and proteins modulating the activity of target cells (84). For instance, studies 
defined the important role of exosomes in mediating paracrine information transfer to 
healing myocardial ischemia/reperfusion injury in mice (61)and pigs (105). Despite 
the bulk of information available on the feasibility and therapeutic outcomes MSC-
based cell therapy did not obtain the expected success in the clinical practice. This is 
due to several factors like documented recovery of immunogenicity associated with 
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MSC differentiation causing late rejection (45), the poor engraftment (58) the short-
term therapeutic benefits (95) and the acquisition of a senescent phenotype following 
several cycles of expansion in vitro. Senescence, in particular, is due to the interplay 
between stochastic and programmed events (41). MSC senescence is triggered by a 
plethora of events mostly regulated by epigenetic phenomena which will be herein 
discussed. 
 
MSCs are not exempted by experiencing aging and senescence: 
regulating mechanisms 
Despite their self-renewal ability, MSC expansion is restricted by the Hayflick 
limit, i.e. the number of times a cell can divide until senescence occurs. At this point 
cell cycle irreversibly stops even though MSCs are still metabolically active. 
Morphologically, senescent MSCs lose their typical spindle-like shape and become 
flat and enlarged with the formation of senescence-associated heterochromatic foci 
linked to the repression of proliferative genes and hence DNA synthesis. The 
mentioned morphological changes reflect a functional impairment since cells lose 
their differentiation potential, thus limiting their therapeutic capacities (114). In a 
sense, senescence is the recapitulation, in the cell, of aging in individuals. However, 
controversy still exists regarding the direct contribution of senescent MSCs to 
organism aging. In any case, senescence is a physiologic event and it is the 
expression of the lack of perfection in biologic systems. Indeed every time a cell 
divides DNA damage accumulates at specific chromosomal regions known as 
telomeres. Telomeres are complexes made of proteins and single-stranded 
nucleotides located at the end of every chromosome and are more sensitive to 
replication damage stress than other chromosomal regions (96,99). Their instability 
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is due to the inability of DNA-polymerase to work on single-stranded sequences. The 
consequence is a shortening of telomeres at every cell division till reaching a critical 
threshold which triggers senescence. Telomeres attrition is generally counteracted 
by telomerase reverse transcriptase (TERT), an enzyme able to add DNA 
sequences at telomeric ends of chromosomes using an RNA template. However, 
telomerase is often poorly expressed in human MSCs and in any case, cannot 
counteract other causes of senescence (9) herein described. 
Changes in the epigenetic regulation of gene expression have been recently 
related to senescent phenotype. Koch and coworkers found that DNA methylation 
varied by 40% between early and late passages, with a general tendency to 
hypomethylation but, in some cases, also hypermethylation was detected. The same 
group proposed an Epigenetic-Senescence-Signature (ESS) based on methylated 
state of specific CpG islets. In particular, they found that two CpG were 
hypermethylated while four were hypomethylated. This ESS significantly correlated 
with cell passage and was found with the same characteristics in MSCs from 
different origins (58). The ESS could thus be a helpful tool to evaluate when MSCs 
go towards senescence and standardize the good manufacturing practices (GMP) 
procedures of in vitro expansion prior to cell therapy as further discussed later in this 
article. 
Other causes of MSC senescence are sustained cytokine stimulation and 
secreted autocrine or paracrine factors, including cytokines, growth factors, 
proteases, and soluble receptors called Senescence-Associated Secretory 
Phenotype (SASP). It has been demonstrated that chronic stimulation with 
antiproliferative cytokines such as Interferon-β (INF-β) and transforming growth 
factor-β (TGF-β) in MSCs induce ROS-mediated p53 or p16ink4a dependent 
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senescence (74,118). More recently, Jin et al. showed that senescent human 
umbilical cord blood-derived MSCs secrete SASP molecules among which the most 
dominant was monocyte chemoattractant potein-1 (MCP-1/CCL2) able to induce 
senescence through binding to its cognate receptor CCR2. In this case, the MCP-1 
release is epigenetically regulated by a decreased level of BMI1, a member of the 
polycomb repressor complex (PRC1) (49). Hence, MCP-1 could be exploited as a 
marker of cell senescence both in vitro and in vivo. Since MCP-1 is secreted also by 
other mural cells such as vascular smooth muscle cells (VSMCs), a MSC-specific 
secretome signature needs yet to be identified. Of note, we reported an increase of 
MCP-1 expression in aortic VSMCs from old rats and humans, pointing at a central 
role of this chemokine in age- and senescence-associated cellular dysfunctions 
(100). Lastly, SASP likely contributes to the correlation between senescent cell 
accumulation and disease onset (125). 
Whatever the trigger is, the effectors of MSCs senescence are molecules 
governing cell cycle progressions like p53 and p16ink4a-pRb. The two pathways act 
both in a concerted way and independently and different are the stimuli activating 
one pathway, the other or both (9,65) (Figure 2).In vitro, senescence is accelerated 
by the oxygen tension used for culturing conditions: MSCs are generally cultured at 
21% O2, a percentage 4 to 10 times higher than the tension they experience inside 
the tissue of origin. The excess of oxygen increases the production of reactive 
oxygen species (ROS) which in turn activate senescence-associated pathways (30). 
 
The oxidative stress theory 
Reactive oxygen species (ROS) are physiological by-products of the oxidative 
metabolism produced during the passage of the reduction equivalents through the 
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mitochondrial electron transport chain. Low physiological ROS concentration is 
beneficial to promote proliferation, DNA stability, and cell survival. This is particularly 
true for MSCs: at steady state, MSCs relies on glycolysis and have a low content of 
ROS as reviewed in (92). In addition, they also have a high content of glutathione, 
and an active antioxidant machinery (111). However, as they replicate, intracellular 
and extracellular senescence-triggering stimuli induce a marked production of ROS. 
High ROS levels damage proteins and DNA especially at telomeric level inducing the 
so-called replicative senescence (48) otherwise known as stress-induced premature 
senescence (108). In this ROS-centric vision of MSC senescence reported as 
oxidative stress theory, ROS act as a molecular “grenade” affecting all cellular 
macromolecules at multi-compartmental level triggering senescence-associated 
pathways (15). The increase in ROS content also correlates with a decrease in cell 
differentiation except for adipogenic differentiation that results increased. In addition, 
under high ROS content, the depotentiation of scavenger systems was observed. 
This phenomenon is due to a decline in the activity of the transcription factor Nrf2, 
which regulates ROS scavenger expression (70). Under physiological conditions, 
Nrf2 is sequestered in the cytoplasm bound to Keap1 protein. Increased ROS 
concentration induces Keap1 detachment and Nrf2 phosphorylation. Huang and co-
workers demonstrated that Protein kinase C (PKC) directly leads to Nrf2 activation 
by phosphorylation (44). Phosphorylated Nrf2 translocates to the nucleus where it 
promotes transcriptional activation of antioxidants scavenging enzymes (heme 
oxygenase-1 [HO-1], NAD(P)H:quinoneoxidoreductase 1 [NQO1], catalase, and 
superoxide dismutase [SOD]) binding to the antioxidant responsive elements (ARE) 
in their promoter regions (19). However, the Nrf2 expression is drastically reduced in 
senescent cells and aging in general (5) thus contributing to increased redox 
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imbalance. Recently, our group found that a specific PKC isoform, PKCβII, plays a 
central role in diabetic complications. PKC is one of the members of a wide family of 
serine/threonine kinases. Following activation by growth factors and ROS, PKC 
becomes active thus regulating diverse pathways through a phosphorylation 
cascade. In our work, PKCβII amplifies oxidative stress in muscular pericytes (MPs) 
isolated from diabetic complicated skeletal muscle. Our results suggest that diabetic 
MPs share common traits with senescent cells since they showed:1) a slowed 
replicative capacity, 2) a reduced myogenic differentiation potential counteracted by 
an increased propensity to adipogenesis, 3) a repression of antioxidant systems and 
4) increased ROS burden. Such a functional impairment is attributable to ROS 
guided activation of the PKCβII-p66Shc signaling pathway (113). In this sense, 
diabetes not only recapitulates but also exacerbates cell senescence. 
 
New players in the control of MSC healthy status: non-coding RNAs  
New post-transcriptional regulators associated with senescence include RNA 
binding proteins (RBPs) and non-coding RNAs both miR and long non-coding RNA 
(lncRNA) classes. Indeed, it is becoming increasingly clear that in addition to coding 
genes, also non-coding RNAs regulate gene expression. MiRs are small, about 20 
nucleotides in length, double strand RNA found intracellular and extracellular, that 
interfere with RNA translation via different mechanisms, the better known implying 
the binding to the 3’UTR sequence of the target gene RNA and the inhibition of 
translation via destabilization/degradation of the transcript. In the nucleus miR 
precursors, pri-miRs, are digested by polymerase II and III to give rise to pre-miRs 
that are sequentially cut by the enzyme Drosha and transported to the cytoplasm 
where mature miRs are generate by the action of Dicer and enter the machinery of 
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mRNA control. Aging and oxidative stress have been associated with dysregulation 
of the fine-tuned miR biogenesis process. Dicer, for example, is reportedly down-
regulated in old rat endothelial cells compared to young donor cells (110). The 
consequent decrease in miRs content impacts on cell capabilities to proliferating, 
adhering, migrating and networking as shown in an experiment in which Dicer was 
reciprocally inhibited or over-expressed in young and old endothelial cells 
respectively. In mice, aging affects the composition of miRs in the adipose tissue, a 
central player in the control of lifespan and diseases. Of the total detected miRs by 
Mori and colleagues, 51% decreased and only 10% of miRs increased when 
comparing 3, 6, and 24-month-old animals. The authors indicate a global decline of 
the miR-generating machinery including Exportin-5 (the enzyme that transport pri-
miRs from the nucleus to the cytoplasm) and Argonaute-2 (a miR-binding protein), 
but the most affected being Dicer. The same authors evidenced that Dicer Knockout 
cells show signs of senescence such as β-galactosidase positivity and up-regulation 
of genes controlling mitochondrial stress pathways (75). Dicer down-modulation was 
confirmed in preadipocytes from old human donors and in the old nematodes model 
pointing at an evolutionarily conserved mechanism. Dicer impairment was efficiently 
reverted by calorie restriction, a strategy that proved beneficial in extending lifespan 
cross-species (31). Of note, in isolated preadipocytes oxidative stress induced by 
H2O2 treatment resulted in Dicer decrease, an effect prevented by insulin treatment. 
Also Exportin-5 and Drosha can be influenced by oxidative stress, although 
the associated mechanisms are still not completely clear (22,103).  
On the other hand, lncRNAs are RNAs of >200 nucleotides in length that do 
not code for proteins (72) comprehending antisense, intronic, and intergenic 
transcripts but also pseudogenes and retrotransposons. The question whether 
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lncRNAs are just byproducts or are actively generated to control cell biology is still 
open. Growing evidence show that they can influence gene expression in multiple 
complex manners, either interacting with DNA, RNA or RBPs. LncRNA effect is at 
the transcriptional and post-transcriptional level and they can either influence 
translation acting as "sponges" for miRs and proteins (13,63). 
The role of non-coding RNAs in cellular senescence has been elegantly 
reviewed recently by Abdelmohsen and Gorospe (1), therefore we will focus here 
only on some MSC-specific aspects (Figure 3). Overall, miRs are known to control 
senescence-associated pathways such as the p16/RB, the p53/p21, and secretory 
moieties related to the aging phenotype. A specific pattern of differentially expressed 
miRs has been associated with senescence in cells including MSCs (35,60). As 
mentioned before, one of the issues about non-coding RNA is still related to 
dissecting whether changes in their profile play an active role in the onset of 
pathologies or it just mirrors the senescence of cell and tissue becoming 
dysfunctional. Some miRs have been validated for their crucial function in MSCs. 
miR-195 is one of them. It has been found elevated in association with MSCs aging 
and senescence together with miR-140, miR-146a/b, but miR-195 functional role 
analysis highlighted a direct control in telomere length as further discussed in this 
article (78). A functional role of the miR-141-3p increase in senescent MSCs was 
also demonstrated by linking it to prelamininA accumulation via miR-141-3p target 
ZMPSTE24 (122). 
miR-335 and miR-452 are two miRs up-regulated in old MSCs from adipose 
tissue (81). MiR-335 has a central role in controlling MSCs proliferation and 
migration as further evidenced by the group of Tomè and coworkers (106,107). The 
authors link the cellular effect of miR-335 to AP-1 activity and to the regulation of 
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members of the FOS family. Interestingly, the secretome of miR-335-MSCs was 
globally augmented pointing at a transition towards the classical SASP condition. 
The forced expression of miR-335 in MSCs in vitro recapitulate several 
aspects of senescence, including the impairment in redox control system, such as 
the reduction in expression of SOD2 and increase in superoxide generation. In this 
respect, it is crucial to note that miRs can themselves control the generation of ROS 
by regulating the Nrf2 pathway as reviewed in (21). On the other hand, in response 
to oxidative stress, a specific pattern of miRs is generated, the prototype being miR-
210 (14,36). After an increase in the level of hypoxia inducible factor-1 (HIF-1) 
protein and of miR-210, the two factors regulate each other in a feedback loop. This 
virtuous cycle is needed for MSC survival in high ROS culture conditions (17,54). 
In a recent article, miR-210 modulation was linked to the beneficial effect in 
protecting MSCs from apoptosis of a redox controlling small molecule called 
zeaxanthin dipalmitate (ZD) (68). 
MiR-34a has been largely associated with aging and cardiovascular diseases 
in particularly affecting the function of cardiovascular cells (7). Confirmation that a 
miR-34a-dependent modulation of the SIRT-1/FOXO3a pathway is controlling MSCs 
vitality similarly to other cell types including ECs has been recently demonstrated 
(46,119,123). 
MiRs exert their action in the cell of origin but also in a paracrine fashion after 
secretion and transfer to a target cells/tissue. This concept has proven true also in 
the context of senescence where secreted miRs can vehicle their action from 
endothelial cells (ECs) to MSCs/pericytes via microparticle shuttling (117). The two 
cell types are in thigh connection and are reciprocally influenced as we also recently 
reviewed. ECs are strongly affected by age and senescence and an SASP condition 
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could apply to ECs too (11,28) (Figure 4). One of such example of extracellular 
shuttled miR is miR-31, a senescence-increased miR known to regulate osteogenic 
differentiation (4) that has been shown to be taken up by MSCs after being released 
in EC-derived microparticles. The inhibition of miR-31 target gene Frizzled-3 is 
associated with osteogenic impairment. This effect was paired with an age-
associated increase in circulating miR-31 in humans. A similar effect was described 
for miR-503, a miR that we found to be dysregulated in diabetes, a pathological 
condition associated with aging and senescence of ECs, that is transferred from ECs 
to pericytes inducing dysfunction (10,12). 
Several hundred lncRNAs are currently known, but their function is still not 
completely understood. A screening in fibroblast demonstrated that the short form of 
lncRNAs is upregulated in senescent cells compared to the long size ones. This 
result reinforces the hypothesis that mRNA stability is altered with aging (2,29). 
Among the emerged lncRNAs associated with senescence, one that has been 
investigated in MSCs with functional consequences is HOTAIR, a lncRNA 
associated with a chromatin locus important for epigenetic changes and that is 
altered in cardiac disease of aging (37,89). In the article by Kalwa et al. the 
expression level of HOTAIR is not changed with in vitro senescence, but its 
modulation alters adipogenic differentiation ability of MSCs. The observed impact on 
the DNA methylation profile of HOTAIR was accompanied by triple helix formation 
(RNA-DNA-DNA) in the down-regulated genes after HOTAIR over-expression (51).  
We expect that several known and new lncRNAs will come into the list of 
senescence controlling factors in the next future since this class of molecules is the 
object of intense research.  
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Epigenetic screening integration with clinical data has a potential 
predictive value for identification of responders to cell therapy. 
Since MSCs are poorly represented in human tissues, culture expansion is 
always necessary prior to use MSCs for cell therapy. This raises the question 
whether the occurrence of senescence can be monitored to avoid administration of 
senescent, non-mitotic cells, which would drive cell therapy failure. Patient-derived 
MSCs display heterogeneous reparative capacity, leading to unpredictable 
therapeutic outcomes and reducing a rigorous clinical application in the whole patient 
population. As mentioned before, attention is now focused on establishing quality 
control assessment at different levels of the standard operating procedure for 
harvesting, isolation, and expansion of cell populations, and on identifying predictors 
able to distinguish responders versus non-responders thereby informing 
personalized therapies (Figure 5). Hemodynamic predictors failed to pass the initial 
validation stage. For instance, the importance of basal contractility indexes such as 
left ventricular ejection fraction (LVEF) in influencing the outcome of cell therapy 
remains controversial. Two recent meta-analyses of bone marrow cell therapy trials 
in patients with acute MI indicate that patients experienced similar improvement in 
LVEF regardless of the baseline LVEF. However, improvements in LVESV were 
more pronounced in patients with lower baseline LVEF (3,8). In contrast, in trials of 
chronic myocardial ischemia, the increase in LVEF elicited by cell therapy was 
significant only in the group with lower LVEF at baseline (8). Remarkable 
advancement in omics technology integrated by the interface with clinical data, e.g. 
the clinomics, promises to bridge basic biological data and benefit on human health. 
Clinomics-based interrogation of stem cell heterogeneity may help deconvolute the 
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heterogeneity of reparative performance thus informing the development of new 
high-fidelity protocols (104). 
Biological markers of MSCs have been already validated as predictors of 
response to autologous stem cell transplantation in patients with neuronal 
degenerative diseases (55). There is still a paucity of data regarding the use of 
epigenetic screening to assess treatment response of cardiovascular MSC therapy. 
We found that patient’s age and smoking habit are negatively associated with 
therapeutic outcomes of pericyte cell therapy in a mouse model of limb ischemia 
suggesting that intrinsic and environmental determinants of senescence could 
impact on cell therapy performance (39). 
To identify new epigenetic predictors of therapeutic activity, we performed a 
whole genome DNA methylation array of the human pericyte populations (39). 
Methylation regulates gene expression by different mechanisms, acting at the 
promoter region and gene bodies. We identified 936 unique genes (106 of these 
involving promoter regions), whose methylation status is correlated with the blood 
flow recovery from ischemia. In addition, 5461 genes (930 in the promoter region) 
had a methylation status that correlates with capillary density in the ischemic muscle, 
and 784 unique genes (of these 89 in the promoter region) were associated with 
arteriole density. Integration of all the differentially methylated genes associated with 
the three outcomes identified 304 genes of which, 158 (52%) bear KROX-/EGR1-
binding sites. The transcription factor KROX/EGR1 couples short-term changes in 
the extracellular environment to long-term changes in gene expression. It is induced 
by different growth factors and chemokines, including VEGF and SDF-1 and 
stimulates microvascular neovascularization through FGF-mediated mechanisms. 
Moreover, the Arf-EGR-C/EBPβ axis is an important determinant of cellular 
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responses (senescence or transformation) to oncogenic Ras signaling (91). An 
analysis of the genomic locations of the 304 genes shared by the three therapeutic 
outcomes, identified a significant enrichment of the 6p21 loci for a gene network 
centered on CREB-binding protein. Such a nuclear protein binds to CREB, which 
restricts cellular senescence and apoptosis (94) and comprises Runt-related 
transcription factor 1 (RUNX1), which belongs to a gene family implicated in stem 
cell plasticity (115). 
The mechanisms that concentrate methylation to specific sequences and loci 
in the genome are unknown, although an interaction between DNA 
methyltransferases and other epigenetic factors has been proposed (87). 
Interestingly, a similar clustering has been observed in studies of gene 
polymorphisms. More than 90% of the genome lacks any disease-associate loci 
according to a meta-analysis of Genome-Wide Association studies (GWAS) of age-
associated diseases (47). Surprisingly, a large spectrum of diseases maps to two 
specific loci 6p21 and INK4/ARF tumor suppressor locus. The former is where the 
major histocompatibility (MCH) locus resides. Genes at this locus determine a high 
susceptibility to a variety of auto-immune diseases and diabetes (47). It is not known 
if mutations at the MCH locus can alter the immune privileged profile of MSCs, which 
normally express low levels of MCH class I (MHCI). In addition, 6p21 emerged as a 
new locus associated with coronary artery disease (CAD) at a genome-wide 
significance from a comprehensive analysis of the extent of pleiotropy of all CAD loci 
(116). Altogether, these reports indicate that polymorphic variants and epigenetic 
modifications at 6p21 loci may have a strong impact on age-associated diseases and 
regenerative processes. 
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In our study on human pericytes, the majority of differentially methylated CpG 
sites were associated with a known transcript. Hence, we next investigated the 
expressional profile using gene arrays (GEO accession number: GSE57964) and 
RT-PCR analyses. This was followed by a gene set enrichment analysis to identify 
transcription factors whose targets are significantly enriched among genes 
correlating with cell therapy outcomes in the limb ischemia model(39). MAZ, a 
transcription factor that emerged from the DNA methylation analysis described 
earlier, was associated with a high number (139) of differentially expressed genes. 
MAZ is a zinc finger transcription factor that binds to GpC rich cis-elements in the 
promoter regions of numerous mammalian genes and is also able to act as a 
recruiting scaffold for different proteins, such as methylases and acetylases, to the 
transcriptional complex, thereby acting as an initiator or terminator of transcription 
(98). The transcription factor plays a role in VEGF-induced angiogenesis under the 
control of microRNA-125b, of which MAZ is an inhibitory target (88,97). Intriguingly, 
the expression of microRNA-125b in pericytes is inversely correlated with their ability 
to induce reparative vascularization in the mouse limb ischemia model. The 
consensus sequence of MAZ-binding sites is very similar to that of Sp1-binding sites. 
In fact, MAZ and Sp1, an anti-senescence transcription factor, bind to the same cis-
elements in the promoters of the genes for endothelial nitric-oxide synthase (eNOS), 
and the receptor for parathyroid hormone (PTHr). However, MAZ acts as a repressor 
and Sp1 as an enhancer of eNOS levels, suggesting they have dual functions in the 
regulation of gene expression. This contrasting action of different zinc-finger proteins 
binding to the same cis-elements is attributable to their capacity to recruiting different 
proteins, such as methylases and acetylases, to the transcriptional complex (98). 
However screening MSCs epigenetic modification alone could be not sufficient to 
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yield a homogeneous population. Attention should be also devoted to the 
microenvironment in which MSCs are grown. ROS load is strictly related to the 
composition of the culture medium and ROS amount holds the balance of power 
between cell differentiation or stemness, proliferation or cell cycle. As the main 
nutrients involved in ROS production are glucose and oxygen, their concentration 
and combination should be precisely defined and keep constant especially during 
GMP procedures (32,56). 
 
The long road from trigger signals to senescence effectors passes 
through the control of reactive oxygen species 
In senescent MSCsROS increase is paralleled by a decrease of Sirtuin 1 
(SIRT1) mediated by its post-transcriptional modulation(93). Studies reveal that 
sirtuins (SIRT1-7), a family of histone deacetylase, act as life span regulating 
proteins and are master regulators of telomeres maintenance (SIRT1 (18) and 
SIRT6 (120)) and DNA repair following oxidative stress (SIRT6 (80)). SIRT1, a 
nuclear isoform of SIRT proteins modulates the activity of different proteins involved 
in cell cycle. p53 is one of the main target (121). In particular, SIRT1 dependent p53 
deacetylation induces p53 inactivity and thus favours cell cycle progression (112). 
However, high ROS levels mediate, from one hand, SIRT1 downregulation, and from 
the other, the upregulation of p53 protein. In this scenario, p53 is also kept in its 
acetylated and inactive state due to the lack of SIRT1. In such a condition the cells 
experience the exit from cells cycle and hence senescence (79). 
Another target of SIRT1 activity is FOXO1, a transcription factor involved in 
the expression of antioxidants enzymes like SODs and catalase. FOXO1 activity is 
regulated by the posttranscriptional mechanism like acetylation. During senescence, 
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the low SIRT1 levels impede FOXO1 deacetylation which is necessary for its 
translocation to the nucleus. As a consequence, the antioxidant machinery under 
senescence condition is repressed (57). Studies report a direct interaction between 
SIRT1 and Nrf2, the activity of which ends up with the up-regulation of multiple 
antioxidant enzymes as previously reported. Analysis of the transcriptional 
complexes binding to ARE sequence detected histone acetyltransferase (HAT) 
p300/CBP along with Nrf2 possibly mediating its acetylation. Acetylation of Nrf2 is 
important to enhance Nrf2 binding to ARE sequences. SIRT1, on the contrary, 
decreases acetylation of Nrf2 as well as Nrf2-dependent gene transcription (53) as a 
compensatory mechanism, even though conflicting results exist. Obviously, 
senescent mesenchymal cells lose such a regulatory mechanisms due to the 
reduced expression of both proteins. So different effectors, such as FOXO1 and Nrf2 
contribute to the increase and maintenance of ROS during senescence and this 
process is mediated by SIRT1. As discussed in the next paragraph, resveratrol has 
been proven to activate SIRT1 over-expression in senescent cells (50). It seems that 
acting at SIRT1 level could be a strategy to potentiate SIRT1 and counteract 
senescence. 
 
Strategies to counteract senescence and improve MSC health and 
therapeutic potentials 
Taking into account all the above-mentioned mechanisms, it appears evident 
that ROS are the main characters of a play (senescence) with a very intricate plot, 
regulated thanks to the interaction among Sirtuins, p53, FOXO1, and Nrf2. 
Strategies to treat or reverse senescence of MSCs could help to counteract aging 
and cell senescence-associated diseases (Figure 6). The efforts should be directed 
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both to isolated cells for regenerative medicine and in vivo. A schematic summary of 
the mechanisms associated with senescence is presented in Table 1. 
Recent studies indicate that resveratrol (3,5,4′-trihydroxy-trans-stilbene), a 
natural phenol produced by several plants in response to injury, do activate SIRT1 
by allosteric interactions that increase SIRT1 affinity for both NAD+ and the 
acetylated substrate (43). In addition, resveratrol treatment improves the osteogenic 
and adipogenic differentiation potential of MSCs (24). In this sense, resveratrol 
mimics the effects of calorie restriction and thus could contribute to extending 
lifespan. Reversing SIRT1 activity could ameliorate different aspect linked to 
senescence, like increase antioxidant enzyme expression through interaction with 
FOXO1 and reactivation of telomerase activity to counteracting telomeres attrition. 
Moreover, resveratrol treatment has been associated with changes in miRs profile, 
supporting the central role of miRs tuning in controlling cellular fate (76,77).  
However, studies in animal models showed that resveratrol supplemented at 
a later life-stage was ineffective (73). Moreover, long-term exposure to resveratrol 
increased MSCs senescence. It is becoming clear that resveratrol effects can be 
beneficial or detrimental depending on the dosage and duration of the treatment. In 
addition, bioavailability following oral administration in mice and humans should be 
taken into account to evaluate the good or bad role of resveratrol treatments. Indeed, 
deeper analysis of blood resveratrol concentration, following oral administration both 
in mice and in humans revealed it is usually lower than the dosage proved to be 
effective in vitro thus adding a bias in the interpretation of results (82). 
Another approach to counteract senescent is modulation of miRNAs known to 
target molecules that regulate directly or indirectly senescence. Okada et al recently 
identified in the bone marrow of old mice a population of mesenchymal cells with 
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features of young mesenchymal cells (YMSCs). Microarray analysis identified a 
different pattern of miRNA in YMSCs with respect to their old counterpart (OMSCs). 
Relevant was the identification of miR-195 that was significantly over-expressed in 
OMSCs. Interestingly a target gene of mir-195 is telomerase reverse transcriptase 
(TERT). Thus, down-regulating miR-195 rejuvenated OMSCs by counteracting 
telomeres attrition (78). MiR modulation can be employed to boost the therapeutic 
capabilities of MSCs as we showed studying human saphenous vein-isolated 
pericytes in a recent work. Transplanted of pericytes in mice infarcted heart resulted 
in improved cardiac function, blood flow recovery, and angiogenesis via paracrine 
signals activation dependent on miR-132 (52). 
More controversial is the role of long non-coding RNA in mediating reversion 
of senescence. The lack of knowledge about their specific function and the multiple 
ways of interaction with nucleic acids and proteins render difficult to target them. 
Clearance of senescent stem cells (SCs) has been exploited in a progeroid 
mouse model using a transgenic approach reportedly delays several age-associated 
disorders (6). Furthermore, selective clearance of senescent SCs by a 
pharmacological agent (ABT263) resulted in the rejuvenation of the stem cell pool in 
bone marrow and skeletal muscles (16). In this context, new strategies to foster the 
clearance of damaged stem cells are emerging. Recently, Cheng and co-workers 
demonstrated that prolonged fasting followed by re-feeding exerts a pro-regenerative 
effect on bone marrow hematopoietic stem cells in mice and humans (20). Whether 
this strategy could be useful for mesenchymal stem cells remains unexplored. 
 
Conclusions 
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The response of cells to time (organism age or passages in culture) by 
slowing proliferation/differentiation and acquiring a secretory phenotype represents 
the effort to counteract accumulating changes and damages. Senescence may, 
therefore, begin for protective reasons, but over time, it limits tissue and cells 
regenerative capabilities. Since MSCs are increasingly recognized as the 
“guardians” of tissue homeostasis for their plastic response to injury, it is of great 
value to dissect the mechanisms that govern MSCs health. Moreover, MSCs can be 
exploited in regenerative medicine approaches after culture expansion. Reviewing 
the hallmarks of MSC changes associated with senescence highlights a central role 
of the redox control. The latter is associated with epigenetic changes that can 
provide a useful tool for selecting regenerative cells. 
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Figure legends 
Figure 1: Overview of senescence in MSCs. MSC senescence is driven by 
diverse events, which occur as the cell, proliferates, like epigenetic modifications, 
DNA damage and ROS accumulation. Those events cause an irreversible cell cycle 
arrest, a change in morphology (spread and enlarged) and an impairment in 
differentiation ability. In addition, senescent cells produce and secrete a series of 
senescence-associated secretory phenotype (SASP) paracrinally mediating 
senescence of close MSCs. 
 
Figure 2: MSC senescence: correlation between ROS and senescence 
regulators. MSCs (left) show a physiologically low ROS content (black spiky dots in 
the figure)which is important to regulate cell proliferation and differentiation. After a 
series of cell divisions, ROS increase, due to an impairment of the radical defense 
system, and accumulate into the cell (right). ROS increaseinduces the 
overexpression of p53 which, once in the nucleus, is easily acetylated (Acp53). 
Although in functional MSCs nuclear p53 can be deacetylated by SIRT1, in 
senescent cells SIRT1 is downregulated thus maintaining p53 acetylated and 
inactive.  
 
Figure 3:Non-coding RNAs contribution to senescent phenotype. Several 
micro RNAs have been demonstrated to regulating senescence-related 
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mechanisms(left). One of them, miR-31 have been reported to be shed from 
senescent endothelial cells asmicroparticle cargo. Once miR-31 is taken up by 
MSCs is sufficient to induce cellular senescence. Less clear is the contribution of 
lncRNAs to senescence for which many mechanisms of action are possible as 
depicted here(right). 
 
Figure 4: Negative influences. Endothelial cells are very sensitive to 
senescence and secrete molecules and microparticles which are paracrine hallmarks 
of senescence. Those include SASP, microRNAs, exosomes and microvescicles that 
induce senescence of MSCs. miRNAs are also shed as microparticle cargo. 
Senescent MSCs in turn influence endothelial cells with similar mechanisms 
however the involvement of miRNA is not that clear.  
 
Figure 5: Deconvolution of patient heterogeneity. Individual variability in 
drug efficacy and safety is a major challenge in current clinical practice. In the case 
of autologous cell therapy, the medicinal product is not homogeneous, and its 
therapeutic activity may vary among cell lines. Integration of clinical data with 
epigenetic screening can help allocate patients to the right treatment. 
 
Figure 6: Strategies to reverse senescence. MSCs senescence can be 
counteracted efficiently using different approaches: potentiating antioxidant defense, 
inhibiting senescence associated RNAs through specific antagonists and increasing 
clearance of senescent cells by phagocytes. These intervention strategies induce the 
decrease of ROS and DNA damage helping the cell to overcome the cell cycle 
blockade, improve MSC differentiation potential and favors morphological recovery.  
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Table 1: Documented causes of MSC senescence  
in vitro Reference in vivo Reference 
High O2 tension in 
culture 
29 SASP 87;61 
DNA methylation 
variation 
55 PROGERIA 59;63;121 
Cytokines, growth 
factors 
71;115 Exosomes 58;102 
SASP 47; 96-122;   
NON coding RNA 20;14-34   
Exosomes 114   
ROS 46;105   
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